1. Home
  2. NAGE vs GBLI Comparison

NAGE vs GBLI Comparison

Compare NAGE & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAGE
  • GBLI
  • Stock Information
  • Founded
  • NAGE 1999
  • GBLI 2016
  • Country
  • NAGE United States
  • GBLI United States
  • Employees
  • NAGE N/A
  • GBLI N/A
  • Industry
  • NAGE Medicinal Chemicals and Botanical Products
  • GBLI Property-Casualty Insurers
  • Sector
  • NAGE Health Care
  • GBLI Finance
  • Exchange
  • NAGE Nasdaq
  • GBLI Nasdaq
  • Market Cap
  • NAGE 861.0M
  • GBLI 443.7M
  • IPO Year
  • NAGE N/A
  • GBLI 2003
  • Fundamental
  • Price
  • NAGE $10.82
  • GBLI $30.08
  • Analyst Decision
  • NAGE Strong Buy
  • GBLI
  • Analyst Count
  • NAGE 2
  • GBLI 0
  • Target Price
  • NAGE $12.00
  • GBLI N/A
  • AVG Volume (30 Days)
  • NAGE 1.2M
  • GBLI 7.8K
  • Earning Date
  • NAGE 05-07-2025
  • GBLI 05-07-2025
  • Dividend Yield
  • NAGE N/A
  • GBLI 4.65%
  • EPS Growth
  • NAGE N/A
  • GBLI N/A
  • EPS
  • NAGE 0.18
  • GBLI 1.99
  • Revenue
  • NAGE $107,925,000.00
  • GBLI $437,447,000.00
  • Revenue This Year
  • NAGE $25.46
  • GBLI $7.67
  • Revenue Next Year
  • NAGE $21.72
  • GBLI $7.93
  • P/E Ratio
  • NAGE $60.46
  • GBLI $15.11
  • Revenue Growth
  • NAGE 29.77
  • GBLI N/A
  • 52 Week Low
  • NAGE $2.31
  • GBLI $26.94
  • 52 Week High
  • NAGE $11.16
  • GBLI $37.00
  • Technical
  • Relative Strength Index (RSI)
  • NAGE N/A
  • GBLI 49.70
  • Support Level
  • NAGE N/A
  • GBLI $30.05
  • Resistance Level
  • NAGE N/A
  • GBLI $31.07
  • Average True Range (ATR)
  • NAGE 0.00
  • GBLI 0.96
  • MACD
  • NAGE 0.00
  • GBLI 0.15
  • Stochastic Oscillator
  • NAGE 0.00
  • GBLI 52.84

About NAGE Niagen Bioscience Inc. Common Stock

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.

Share on Social Networks: